ClinicalTrials.gg
RecruitingNCT07403669CHAPERONE-CKMUpdated Feb 12, 2026

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

An interventional study of CHAPERONE AI and CKMiq AI in Acute MI, Heart Failure and Diabetes Mellitus, sponsored by Aventyn, Inc.. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Aventyn, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2025, registered Feb 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
367th of 1,602
300 · median 66
Started
2025
with 107 others
No phase
887 of 2,159
159 open now
Primary completion
2026-10
later than 109 of 438 live
Registered
2,095th of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 367th largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 108 that started in 2025, is one of 887 with no phase, reaches primary completion later than 109 of the 438 other live ones, and was the 2,095th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.

Read the detailed description

The interconnectedness between Diabetes, Heart disease and Kidney disease (Cardio Kidney Metabolic) has never been more important to recognize than the present day as the current data on the prevalence of this trifecta suggests an exponential increase in comorbidity, death, poor quality of life and a colossal economic burden on the society. Risk factors such as hypertension, high cholesterol, smoking, prediabetes states, obesity, unhealthy eating habits, lack of exercise, micro particle air pollution, high inflammatory markers, life stressors and genetics play a significant role in triggering the onset of these diseases and their complications. Half a Billion people in the world are expected to be having diabetes by 2023; another 150 million with prediabetes and one billion with hypertension ( Already 130Million in the US have Hypertension now )

Problem of Kidney Disease:

More than 37 million Americans have kidney disease and millions more are at risk. According to the Centers for Disease Control and Prevention (CDC), 9 out of 10 people with early kidney disease don't know they have it because it usually has no symptoms until the late stages. Simple blood and urine tests can tell how well the kidneys are working. Diabetes and high blood pressure are the two leading causes of kidney disease. Kidney disease can lead to heart attack, stroke, kidney failure and death. With recent advances in research, Kidney disease can be treated if caught and treated early and it is often possible to slow or stop the progress of kidney disease with diet, exercise, lifestyle modifications and a few newer medications. Besides diabetes and high blood pressure, other common risks for kidney disease include having a family history of kidney disease, Black heritage, Hispanic, Asian American, or Native American. Black Americans are 3.4 times more likely than whites to develop kidney failure if over 60 years of age, and Hispanics are 1.5 times more likely than non- Hispanics to develop kidney failure. There are more than 785,000 people with kidney failure in the United States-an increase of more than 100% since 2000.

03

Conditions studied

  • Acute MI
  • Heart Failure
  • Diabetes Mellitus
  • Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women over 18 years of age are included
  • Eligible subjects must have one of the risk factor/ disease component of CKM:
  • Diabetes with of 7.5 or higher;
  • or Heart disease with stent placement;
  • or Coronary Artery Bypass Graft (CABG) in the last 12 months;
  • or Chronic Kidney Disease (CKD) stage 2- 4
  • and, in those with Heart failure, a recent hospitalization within one week of enrollment is required

Exclusion criteria

Exclusion Criteria:

  • Those subjects who are not willing to sign an
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Placebo comparator
    Intervention

    All qualified cardio kidney metabolic (CKM) patients including Congestive Heart Failure (CHF) subjects in Intervention Arm

    Other: CHAPERONE AI · Device: CKMiq AI · Other: Quality of Life

  • No intervention
    Control

    All qualified cardio kidney metabolic patients including CHF subjects in control arm

Interventions

  • OtherCHAPERONE AI

    The primary objective of this study is to evaluate the efficacy of treatment strategy on the impact of an intervention that is AI, Machine Learning (ML) based using Chatbot and Copilot with algorithm based intervention in CKM subjects in reducing progression of CKM diseases. This will be based on an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment. Improvement of patient outcomes will be measured by reduction of composite of Kidney failure/progression of kidney disease, Heart failure, acute myocardial infarction (AMI) events and diabetes complications and hospitalization as well as all-cause mortality through 30 days, 90 days and 180 days in CKM patients

  • DeviceCKMiq AI

    To evaluate the effect of treatment in: reducing readmission's from cardiovascular causes using an algorithm-based intervention of LIFE ESSENTIAL 8 biomarkers obtained from info graphic resources provided by American Heart Association. Improving subject self-assessed risk score overall well-being as measured by self-assessed Copilot Likert scale at 30 days, 90 days and 180 days from hospitalization. Increasing the number of days alive and outside the hospital from hospitalization through day 30, 90 and Day 180. Reducing the composite of cardiovascular re-hospitalization and cardiovascular mortality from hospitalization through 30, 90 and 180 days. New York Heart Association (NYHA) Class and Kansas City Cardiomyopathy Questionnaire (KCCQ) will be captured.

  • OtherQuality of Life

    Secondary and tertiary objectives of this study are to evaluate the effect of CHAPERONE intervention in: Improving LIFE ESSENTIAL-8 Score and Health Related Quality of Life (HRQOL) measured with the 12-item Short Form (SF-12) survey, which reflects general health status and leads to 2 scores

    Also known as: CKM QOL

06

What researchers measure

Primary outcomes

  1. CHAPERONE AI Treatment

    Improvement of patient outcomes will be measured by reduction of composite of Kidney failure/progression of kidney disease, Heart failure, Acute Mi events and diabetes complications and hospitalization as well as all-cause mortality through 30 days, 90 days and 180 days in patients CKM

    Time frame: 30 days, 90 days and 180 days in patients CKM

Secondary outcomes

  1. CHAPERONE AI Reduced Readmissions

    educing readmissions from cardiovascular causes using an algorithm-based intervention of LIFE ESSENTIAL 8 biomarkers obtained from infographic resources provided by American Heart Association , improving subject self-assessed risk score overall well-being as measured by self-assessed Copilot Likert scale at 30 days, 90 days and 180 days from hospitalization Increasing the number of days alive and outside the hospital from hospitalization through day 30, 90 and Day 180. Reducing the composite of cardiovascular re-hospitalization and Cardiovascular mortality from hospitalization through 30, 90 and 180 days. NYHA class and KCCQ will be captured

    Time frame: 30, 90 and 180 days.

07

Study locations

2 of 5 sites recruiting
  • Fountains Family Care
    Chandler, Arizona 85248, United States
    Completed

    Not enrolling at this site.

  • Gilbert Cardiology
    Gilbert, Arizona 85297, United States
    Recruiting
    • Sharolyn McClurg Coordinator, MSN, CNP · Contact
  • Arizona Heart Foundation
    Phoenix, Arizona 85014, United States
    Recruiting
    • Eileen Spengler, RCS, FASE · Contact
    • Eileen Spengler, RCS, FASE · Sub investigator
  • East Valley Diabetes
    San Tan Valley, Arizona 85143, United States
    Completed

    Not enrolling at this site.

  • Karolinska University Hospital
    Stockholm, Sweden
    Not yet recruiting
    • Marcus Stahlberg, MD · Contact
    • Marcus Stahlberg, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 12 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 11, 2026
StartActual
Oct 22, 2025
Primary completionEst.
Oct 22, 2026
CompletionEst.
Apr 22, 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07403669
Lead sponsor
Aventyn, Inc.
Collaborators
Dignity Health, Arizona Heart Foundation, Arizona State University, University of Arizona, University of Phoenix College of Nursing, Creighton School of Medicine, Phoenix Arizona, Karolinska University Hospital, Partnership for Economic Innovation Arizona, Kanasu Labs, Intel Corporation
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Oct 22, 2025
Primary completion
Oct 22, 2026 (estimated)
Completion
Apr 22, 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Navin Govind Steering Committtee, MS
Contact
info@aventyn.com
2317942328
Aditya Vijay, MS
Contact
2317942328
Kris Vijay Study Chair, MD
study chair · Aventyn, Inc.
Zaki Lababidi PI, MD
principal investigator · Gilbert Cardiology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion